The osteoporosis treatment crisis isn't about a shortage of drugs,it's about a shortage of patients actually taking them. Less than 15% of people who have already suffered an osteoporotic fracture are prescribed medication to prevent future breaks, according to recent analysis. Yet instead of addressing this treatment gap, the U.S. Food and Drug Administration (FDA) recently changed how it approves new osteoporosis medications in ways that could create new safety problems down the road.

What Changed in Osteoporosis Drug Approval?

In a significant regulatory shift, the FDA moved away from requiring clinical fracture prevention as the gold standard for approving new osteoporosis drugs. Instead, the agency now accepts bone density as a "surrogate end point," meaning pharmaceutical companies can demonstrate that a drug increases bone density without proving it actually prevents fractures. This change also allows clinical trials to shrink dramatically: from several thousand participants down to several hundred, and from multi-year studies to just 24 months.

The reasoning seemed sound. A coalition of pharmaceutical companies and members of the American Society for Bone and Mineral Research argued that faster approvals would spur innovation and get more medications to patients who need them. But the logic has a critical flaw: bone density alone doesn't tell the whole story about whether a drug actually keeps bones from breaking.

Why Bone Density Isn't the Whole Picture?

The FDA's decision was based on a careful analysis of past clinical trials showing a strong relationship between bone density and fracture risk. However, this analysis left out one crucial piece of evidence: a randomized trial of fluoride, a medication that increased spine bone density more than virtually any other osteoporosis drug available. The problem? Fluoride was associated with a higher rate of actual clinical fractures compared to placebo. This real-world failure demonstrates why bone density alone can be misleading.

The deeper issue involves how bone actually works over time. Bone is constantly repairing microscopic damage, a process that becomes less efficient with age. On average, trabecular bone (the spongy interior) completely turns over every five years, while cortical bone (the dense outer layer) takes roughly twice as long. Medications that slow bone turnover don't show their problems in short-term trials, but over years, microscopic damage accumulates and weakens the bone structure.

The Long-Term Safety Risks Experts Are Concerned About

Several widely used osteoporosis medications carry risks that only emerge with extended use. Bisphosphonates and denosumab, two of the most common treatments, increase the risk of atypical femur fractures (unusual breaks in the thighbone) the longer patients take them. Other newer medications like teriparatide, denosumab, and romosozumab increase bone density while being used, but that benefit disappears once treatment stops, raising questions about long-term strategy.

Beyond bone itself, osteoporosis medications can affect other body systems in ways that take years to become apparent. Bone plays a role in regulating acid levels and storing minerals and proteins throughout the body. Additionally, the cardiovascular system is intimately connected to bone health; cells in blood vessel walls can transform into bone-forming cells, which can lead to dangerous calcium deposits in arteries. This process is especially problematic in people with kidney disease but also occurs with normal aging.

History provides a cautionary tale. Strontium, a medication that increased bone density on imaging tests, was approved by European regulators but later lost approval due to increased cardiovascular disease risk. Cathepsin K inhibitors showed early promise for osteoporosis treatment but were found to increase stroke risk after two years of use.

Steps to Address the Real Treatment Gap

• Patient Education: Many patients and physicians don't view osteoporosis as a serious condition worthy of treatment, despite its role in causing fractures and disability. Better counseling about accurate risk-benefit assessments of medications could improve treatment rates.
• Physician Training: A shortage of doctors specializing in osteoporosis treatment exists, partly because insurance denials for newer medications require physicians to spend hours on appeals, making the specialty less attractive.
• Non-Drug Approaches: Hip protectors effectively reduce fracture risk if worn consistently, thiazide diuretics mildly increase bone density and reduce hip fracture risk by 24% in pooled studies, and tai chi may reduce fracture risk through improved balance and strength.

The real opportunity for preventing osteoporotic fractures lies in intervening early, before significant bone loss occurs. The critical window is perimenopause, the years surrounding a woman's final menstrual period. Detailed bone imaging shows that bone loss is greatest in the year before and year after menopause.

A four-year randomized trial of women aged 40 to 60 demonstrated this principle clearly. Women receiving a placebo lost 2.9% of bone density at the hip, while those taking alendronate (a bisphosphonate) gained 1.4%, and those on estrogen gained 3.7%. The large, federally funded Study of Osteoporotic Fractures found that women who took estrogen starting at menopause and continued for an average of 35 years had lower fracture risk throughout an 11-year follow-up period.

Estrogen works differently than bisphosphonates or denosumab. Rather than aggressively suppressing bone turnover, estrogen slows bone loss while supporting the lifespan of bone-building cells, which means it doesn't carry the same risk of atypical fractures or jaw bone death that comes with long-term use of other medications. The Women's Health Initiative study showed fracture reduction in women taking estrogen regardless of age, though cardiovascular benefits depend on timing. Women within a decade of menopause showed cardiovascular benefit, while older women showed harm, which is why most physicians have stopped prescribing it. Recent research suggests transdermal estrogen dosing (delivered through a patch) may be safer, with lower clotting risk than oral forms.

A recent trial also showed promise for a single dose of zoledronate in women aged 50 to 60, reducing fracture risk from 11.1% to 6.6% compared to placebo. The bone resorption markers decreased but gradually increased again, suggesting the bone could repair microscopic damage without the long-term suppression problems associated with extended bisphosphonate use.

"We need better choices for osteoporosis medication. The new U.S. FDA requirements could result in more research, but physicians must be aware of the new safety standards. Meanwhile, we can provide more clear and accurate education about the benefits and risks of current medications, especially estrogen, which is underused and poorly understood," noted Susan Ott in an opinion piece for JAMA Network.

Susan Ott, Physician and Osteoporosis Researcher

The timing of bone density screening itself remains controversial. If screening doesn't occur until age 65, it's too late to start estrogen or prevent the rapid bone loss that happens after menopause. Bone density screening could be offered to women at menopause if they want to know their fracture risk and if it would help them decide about taking medications, given that screening tests are inexpensive and the physiologic effects of estrogen on bone are well understood.

The FDA's push for faster drug approvals reflects genuine frustration with the treatment gap, but it addresses the wrong problem. The real barriers to preventing osteoporotic fractures aren't a lack of medications,they're inadequate patient education, physician shortages in the specialty, high medication costs, and a missed opportunity to intervene during perimenopause when prevention is most effective. Approving drugs faster based on bone density alone risks repeating past mistakes, while the patients who need treatment most remain untreated.